MIRA Pharmaceuticals, Inc. filed a Form 8-K on November 16, 2026, disclosing new pharmacological findings for its investigational oral drug candidate MIRA-55, including receptor selectivity data and an update on preclinical development plans.

Key Highlights

  • Opioid receptor separation: Expanded receptor screening showed more than 500-fold separation between MIRA-55's CB2 receptor activation and its measured interactions with mu, delta, and kappa opioid receptors, respectively, according to the filing.
  • COX inhibition absent: MIRA-55 showed no substantial inhibition of COX-1 or COX-2 at the tested concentrations, the company disclosed.
  • Prior animal study comparisons: Previously reported studies demonstrated greater pain relief than injected morphine in an acute inflammatory pain model and sustained pain relief comparable to celecoxib in a separate chronic inflammatory pain study, under the conditions tested.
  • Behavioral findings: Additional animal studies showed an anxiolytic-like signal and encouraging exploratory behaviors, alongside the absence of significant THC-like motor impairment, the filing stated.
  • IND submission target: The company disclosed it is targeting an Investigational New Drug (IND) submission in the first half of 2027.
  • Press release planned: The company stated it intends to distribute a press release regarding these findings on November 17, 2026.

MIRA Pharmaceuticals Discloses Receptor Selectivity Profile for MIRA-55

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), an emerging growth company headquartered in Miami, Florida, furnished new pharmacological data for MIRA-55 under Item 7.01 Regulation FD Disclosure of its November 16, 2026 Form 8-K. According to the filing, expanded receptor screening demonstrated "substantial separation" between MIRA-55's potent CB2 receptor activation and interactions with other biological targets, including more than 500-fold separation from mu, delta, and kappa opioid receptors, respectively. The company also reported no substantial inhibition of COX-1 or COX-2 at the tested concentrations.

The filing described how the new data build on previously reported work showing potent CB2 activation, measurable CB1 activity, brain penetration following oral administration in animals, and distinct effects on beta-arrestin and Gi/cAMP signaling. The company stated that MIRA-55's brain penetration "may provide an opportunity to influence central pain-processing pathways in addition to peripheral inflammation." Its pathway-dependent pharmacology, described as inhibition of agonist-induced beta-arrestin recruitment with limited antagonism of Gi/cAMP signaling, "may also provide a potential basis for a differentiated CNS behavioral profile," according to the filing.

Regarding prior animal study results, the filing noted greater pain relief than injected morphine in an acute inflammatory pain model and sustained pain relief comparable to celecoxib in a separate chronic inflammatory pain study, under the conditions tested. The company stated it is advancing MIRA-55 through preclinical and IND-enabling activities and is targeting an IND submission in the first half of 2027. The filing noted that all statements regarding therapeutic potential and development plans are forward-looking and subject to risks and uncertainties identified in the company's regulatory filings.

What Was Disclosed

MIRA Pharmaceuticals furnished new receptor selectivity and pharmacological data for MIRA-55 via a Regulation FD disclosure on November 16, 2026, including opioid receptor separation figures, COX inhibition results, prior animal study comparisons, and an IND submission target of the first half of 2027.